Having a clear, board-backed market access strategy from early on is essential to a company’s success. It provides a critical lever to use with regulators and payers to realize the full clinical and commercial potential of your assets, and the value of your product(s) and company. It will also ensure that your therapies benefit as many patients as possible. As governments increasingly scrutinize drug pricing and healthcare costs, and payers and regulators are focused on differentiated treatments that maximize value and minimize costs, its importance grows in significance.

Our expert panel will walk you through the fundamentals of creating and executing on a market access strategy, plan from preclinical through commercialization, and provide insights as how to best go about it whether you are a starving start-up, a high profile pre-commercial biotechm, or an established multi-national company.


Who will benefit from this forum:

- Early stage companies focused on proving their science and attracting investors
- Later stage companies who want to maximize their value at exit or at first product launch

Sponsored by the MassBio MarComm and Commercial working group.